Search

Rindopepimut

The US FDA granted it Breakthrough Therapy Designation for glioblastoma in Feb 2015. … Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases.

LM-609

In addition to cancer, the protein has been implicated in bone destruction in rheumatoid arthritis and the inflammatory process in psoriasis. … LM-609 (Vitaxin) is an artificial antibody that targets a protein on the surface of newly forming blood vessels, as well as on certain tumors.

Podofilox

A lignan found in podophyllin resin from the roots of podophyllum plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. … It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives

Sitamaquine

Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential

Affitope AD01

AD01 is a short peptide (7 amino acids in length) that induces Aß-targeting antibodies, therefore lowering Aß aggregates. … Affitope AD01 is an investigational drug developed for immunization to treat Alzheimer's Disease.

Indecainide

Indecainide is a rarely used antidysrhythmic. … Indecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics

SSR-126517E

SSR-126517E is a second generation synthetic pentasaccharide that binds antithrombin with such high affinity that it assumes a plasma half-life of 80 hours.

Iodohippuric acid

Iodohippuric acid is under investigation in clinical trial NCT02599844 (Impact of Pediatric Acute Renal Injury in Severe Sepsis in Young Adults).

Alglucerase

Alglucerase was first approved by the FDA in 1991;[A254816] however, it was later discontinued from the market. … Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase.

Dodecyldimethylamine N-oxide